Press Releases

Jazz Pharmaceuticals Investor & Media Relations
Investors: investorinfo@jazzpharma.com
Media: mediainfo@jazzpharma.com
Ireland, +353 1 634 7892
U.S., +1 650 496 2800
Keyword Search
 
2015 | 2014 | 2013 | 2012
DateTitle  
02/24/15Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2014 Financial Results
Company Reports Total Revenues of $1.17 Billion in 2014 Driven by Strong Sales of Xyrem, Erwinaze and Defitelio Adjusted EPS of $8.43 and GAAP EPS of $0.93 in 2014 DUBLIN, Feb. 24, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter ended December 31, 2014 and provided financial guidance for 2015. "2014 was an outstanding year for Jazz Pharmaceuticals as we executed on our growth strategy, delivered stro... 
 Printer Friendly Version
02/23/15Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March
DUBLIN, Feb. 23, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.  Cowen and Company 35th Annual Healthcare Conference in Boston, MA on Monday, March 2, 2015 at 1:30 p.m. EST / 6:30 p.m. GMT. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update. Barclays Global Healthcare Conference in ... 
 Printer Friendly Version
02/12/15Jazz Pharmaceuticals Launches Educational Campaign to Raise Awareness of Hepatic Veno-Occlusive Disease (VOD)
... 
Printer Friendly Version
02/12/15Jazz Pharmaceuticals to Present Data on Defibrotide, an Investigational Treatment, in Patients with Hepatic Veno-Occlusive Disease (VOD) at BMT Tandem Meetings
Three Oral Presentations Provide New Analyses of the Efficacy and Safety of Defibrotide in Patients with VOD, Including Post-Hoc Sub-Group Analyses in Children, Adults, and Allograft and Autograft Recipients DUBLIN, Feb. 12, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that researchers will present data on the use of defibrotide, an investigational medicine being studied in the United States (U.S.) for the treatment of hepatic veno-occlusive disease (VOD), a ra... 
 Printer Friendly Version
02/10/15Jazz Pharmaceuticals to Report 2014 Fourth Quarter and Full Year Financial Results on February 24, 2015
DUBLIN, Feb. 10, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 fourth quarter and full year financial results on Tuesday, February 24, 2015, after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to discuss fourth quarter and full year 2014 financial results and provide a business and financial update and guidance for 2015 financi... 
 Printer Friendly Version
01/05/15Jazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 12
DUBLIN, Jan. 5, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.  Bruce C. Cozadd, chairman and chief executive officer, will provide an overview of the company and provide a business and financial update at the conference on Monday, January 12, 2015 at 10:00 a.m. PST / 6:00 p.m. GMT. A live audio webcast of the presentation ... 
 Printer Friendly Version